Overweight and obesity seriously damages human health. The World Health Organization
estimates that 1.5 billion adults were overweight in the year of 2011. Of this overweight …

Aims To determine the effects of glucagon-like peptide-1 receptor agonists compared with
placebo and other anti-diabetic agents on weight loss in overweight or obese patients with …

Objective To determine whether treatment with agonists of glucagon-like peptide-1 receptor
(GLP-1R) result in weight loss in overweight or obese patients with or without type 2 …

To evaluate the effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on
weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta …

After ingestion of carbohydrate-and fat-rich meals, the incretin hormone glucagon-like
peptide 1 (GLP-1) is secreted from the L-cells in the distal put into the circulation. Its major …

Abstract Glucagonlike peptide 1 (GLP-1) is an insulinotropic hormone secreted from
endocrine cells in the gut mucosa in response to meal ingestion. It is an important incretin …

Glucagon‐Like Peptide‐1 receptor agonists (GLP‐1RAs), approved as glucose‐lowering
drugs for the treatment of type 2 diabetes, have also been shown to reduce body weight. An …

Background: Obesity can seriously damage human health and have the potential to raise
the likelihood of diabetes mellitus (DM) and other adverse outcomes. Successful therapeutic …

The gastrointestinal hormone glucagon‐like peptide‐1 (GLP‐1) lowers postprandial glucose
concentrations by regulating pancreatic islet‐cell function, with stimulation of glucose …

Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L cells of the
intestine in response to food. Exogenous GLP-1 administration at pharmacological doses …